Global Point of Care (PoC) Testing Market By Product (Testing Type) (Glucose monitoring, Cardiometabolic Monitoring, Albumin Testing, Infectious disease testing – HIV Infections, Malaria, Syphilis, E. Coli, Influenza, Others, Coagulation monitoring, Pregnancy and fertility testing, Cancer marker testing, Urine analysis testing, Cholesterol testing, Hematology testing, Drugs-of-abuse testing, Fecal Occult testing, Covid-19 testing, Others); By Distribution Channel (Prescription Based, Over The Counter (OTC)); By End-user (Hospitals – Critical Care Units, Neonatal Intensive Care Unit (NICU), Others, Private Clinics, Diagnostic Centres, Home Care Settings, Ambulatory Care Centers, Emergency Departments, Laboratories, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Point-of-care (POC) testing also known as bedside testing happens to be medical diagnostic testing, which is done at the time and place of the care of the patient. This type of testing is completely different than conventional testing that used to be conducted in a medical laboratory, which most of the times is located in a hospital. This is utterly convenient from the patient’s point of view, specifically those who cannot visit the testing centres due to some reason. This is the biggest reason why the global point of care (PoC) testing market is growing at a fantastic speed. Well, these types of tests happen to be normal medical tests that can be performed at any time. This is very much possible due to rapid technological advancement. Technology like the portable ultrasonography have made conducting tests like urine tests extremely easy. Just like this, the pulse oximetry is capable of testing arterial oxygen saturation in fast, simple, non-invasive, and utterly affordable. Not just bigger hospitals, but several private players are entering the medical sector and setting up laboratories that provide point of care testing services. Along with testing kits are being manufactured and sold over the counters in most of the countries. This also provides impetus to the growth of this market.
The point of care testing proved extremely helpful during the coronavirus pandemic. Oximeters were used extensively to understand the levels of the oxygen that is likely to be infected with the life-threatening SARS-CoV-2 virus. This is the reason why the global point of care (PoC) testing market flourished in the period of the COVID-19 pandemic.
In terms of revenue, the global point of care (PoC) testing market was valued at US$ 42.6 Bn in 2021 growing at a CAGR of 11% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Point of Care (PoC) Testing Market Revenue & Forecast, (US$ Million), 2015 – 2030
Product (Testing Type) Outlook:
Based on the product type outlook, the global point of care (PoC) testing market has been segmented into glucose monitoring, cardiometabolic monitoring, albumin testing, infectious disease testing, coagulation monitoring, pregnancy and fertility testing, cancer marker testing, urine analysis testing, cholesterol testing, hematology testing, drugs-of-abuse testing, fecal occult testing, Covid-19 testing, and others. Infectious disease testing segment has been bifurcated into HIV infections, malaria, syphilis, E. Coli, influenza, and others. The glucose monitoring segment accounts for majority of revenue generated by this market. The number of people suffering from type-2 diabetes are growing rapidly and this is why they need point of care testing.
Region Outlook:
Based on region, the North America makes most of the money for the global point of care (PoC) testing market in the year 2021. Fantastic medical infrastructure, along with rising number of people suffering from various ailments like hypertension and diabetes in the countries like the United States and Canada is growing. The convenience that point of care testing brings along extreme convenience and this drives the growth of this market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global point of care (PoC) testing market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Competitors: Global Point of Care (PoC) Testing Market
- Abbott
- AccuBioTech Co. Ltd
- BD
- Beckman Coulter, Inc.
- Chembio Diagnostics, Inc.
- Danaher
- EKF Diagnostics
- F. Hoffmann-La Roche Ltd
- PTS Diagnostics
- Sekisui Diagnostics
- Siemens Healthcare Private Limited
- Thermo Fisher Scientific
- Trinity Biotech
- Other Market Participants
Global Point of Care (PoC) Testing Market:
By Product (Testing Type)
- Glucose monitoring
- Cardiometabolic Monitoring
- Albumin Testing
- Infectious disease testing
- HIV Infections
- Malaria
- Syphilis
- E. Coli
- Influenza
- Others
- Coagulation monitoring
- Pregnancy and fertility testing
- Cancer marker testing
- Urine analysis testing
- Cholesterol testing
- Hematology testing
- Drugs-of-abuse testing
- Fecal Occult testing
- Covid-19 testing
- Others
By Distribution Channel
- Prescription Based
- Over The Counter (OTC)
By End-user
- Hospitals
- Critical Care Units
- Neonatal Intensive Care Unit (NICU)
- Others
- Private Clinics
- Diagnostic Centres
- Home Care Settings
- Ambulatory Care Centers
- Emergency Departments
- Laboratories
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 - 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Point of Care (PoC) Testing
Market
6.
Market
Synopsis: Point of Care (PoC) Testing
Market
7.
Point of Care (PoC) Testing Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Point of Care (PoC) Testing Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic
Indicators: Point of Care (PoC) Testing
Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Point of Care (PoC) Testing Market
8.
Global Point of Care (PoC) Testing Market Analysis
and Forecasts, 2022 - 2030
8.1. Overview
8.1.1. Global
Point of Care (PoC) Testing Market Revenue (US$ Mn)
8.2. Global
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
8.2.1. Glucose monitoring
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Cardiometabolic Monitoring
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Albumin Testing
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Infectious disease testing (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast
(2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on HIV Infections, Malaria, Syphilis, E.Coli, Influenza, Others)
8.2.4.1.
HIV
Infections
8.2.4.2.
Malaria
8.2.4.3.
Syphilis
8.2.4.4.
E.Coli
8.2.4.5.
Influenza
8.2.4.6.
Others
8.2.5. Coagulation monitoring
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Pregnancy and fertility testing
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.2.7. Cancer marker testing
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.7.3.
Market
Forecast, 2022 - 2030
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 - 2021
8.2.7.5.1.2. Market Forecast, 2022 - 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2021
8.2.7.5.2.2. Market Forecast, 2022 - 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2021
8.2.7.5.3.2. Market Forecast, 2022 - 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2021
8.2.7.5.4.2. Market Forecast, 2022 - 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 - 2021
8.2.7.5.5.2. Market Forecast, 2022 - 2030
8.2.8. Urine analysis testing
8.2.8.1.
Definition
8.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.8.3.
Market
Forecast, 2022 - 2030
8.2.8.4.
Compound
Annual Growth Rate (CAGR)
8.2.8.5.
Regional
Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 - 2021
8.2.8.5.1.2. Market Forecast, 2022 - 2030
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 - 2021
8.2.8.5.2.2. Market Forecast, 2022 - 2030
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 - 2021
8.2.8.5.3.2. Market Forecast, 2022 - 2030
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 - 2021
8.2.8.5.4.2. Market Forecast, 2022 - 2030
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 - 2021
8.2.8.5.5.2. Market Forecast, 2022 - 2030
8.2.9. Cholesterol testing
8.2.9.1.
Definition
8.2.9.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.9.3.
Market
Forecast, 2022 - 2030
8.2.9.4.
Compound
Annual Growth Rate (CAGR)
8.2.9.5.
Regional
Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 - 2021
8.2.9.5.1.2. Market Forecast, 2022 - 2030
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 - 2021
8.2.9.5.2.2. Market Forecast, 2022 - 2030
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 - 2021
8.2.9.5.3.2. Market Forecast, 2022 - 2030
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 - 2021
8.2.9.5.4.2. Market Forecast, 2022 - 2030
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 - 2021
8.2.9.5.5.2. Market Forecast, 2022 - 2030
8.2.10. Hematology testing
8.2.10.1. Definition
8.2.10.2. Market Estimation and Penetration, 2015 -
2021
8.2.10.3. Market Forecast, 2022 - 2030
8.2.10.4. Compound Annual Growth Rate (CAGR)
8.2.10.5. Regional Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 - 2021
8.2.10.5.1.2. Market Forecast, 2022 - 2030
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 - 2021
8.2.10.5.2.2. Market Forecast, 2022 - 2030
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 - 2021
8.2.10.5.3.2. Market Forecast, 2022 - 2030
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 - 2021
8.2.10.5.4.2. Market Forecast, 2022 - 2030
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 - 2021
8.2.10.5.5.2. Market Forecast, 2022 - 2030
8.2.11. Drugs-of-abuse testing
8.2.11.1. Definition
8.2.11.2. Market Estimation and Penetration, 2015 -
2021
8.2.11.3. Market Forecast, 2022 - 2030
8.2.11.4. Compound Annual Growth Rate (CAGR)
8.2.11.5. Regional Bifurcation
8.2.11.5.1. North America
8.2.11.5.1.1. Market Estimation, 2015 - 2021
8.2.11.5.1.2. Market Forecast, 2022 - 2030
8.2.11.5.2. Europe
8.2.11.5.2.1. Market Estimation, 2015 - 2021
8.2.11.5.2.2. Market Forecast, 2022 - 2030
8.2.11.5.3. Asia Pacific
8.2.11.5.3.1. Market Estimation, 2015 - 2021
8.2.11.5.3.2. Market Forecast, 2022 - 2030
8.2.11.5.4. Middle East and Africa
8.2.11.5.4.1. Market Estimation, 2015 - 2021
8.2.11.5.4.2. Market Forecast, 2022 - 2030
8.2.11.5.5. Latin America
8.2.11.5.5.1. Market Estimation, 2015 - 2021
8.2.11.5.5.2. Market Forecast, 2022 - 2030
8.2.12. Fecal Occult testing
8.2.12.1. Definition
8.2.12.2. Market Estimation and Penetration, 2015 -
2021
8.2.12.3. Market Forecast, 2022 - 2030
8.2.12.4. Compound Annual Growth Rate (CAGR)
8.2.12.5. Regional Bifurcation
8.2.12.5.1. North America
8.2.12.5.1.1. Market Estimation, 2015 - 2021
8.2.12.5.1.2. Market Forecast, 2022 - 2030
8.2.12.5.2. Europe
8.2.12.5.2.1. Market Estimation, 2015 - 2021
8.2.12.5.2.2. Market Forecast, 2022 - 2030
8.2.12.5.3. Asia Pacific
8.2.12.5.3.1. Market Estimation, 2015 - 2021
8.2.12.5.3.2. Market Forecast, 2022 - 2030
8.2.12.5.4. Middle East and Africa
8.2.12.5.4.1. Market Estimation, 2015 - 2021
8.2.12.5.4.2. Market Forecast, 2022 - 2030
8.2.12.5.5. Latin America
8.2.12.5.5.1. Market Estimation, 2015 - 2021
8.2.12.5.5.2. Market Forecast, 2022 - 2030
8.2.13. Covid-19 testing
8.2.13.1. Definition
8.2.13.2. Market Estimation and Penetration, 2015 -
2021
8.2.13.3. Market Forecast, 2022 - 2030
8.2.13.4. Compound Annual Growth Rate (CAGR)
8.2.13.5. Regional Bifurcation
8.2.13.5.1. North America
8.2.13.5.1.1. Market Estimation, 2015 - 2021
8.2.13.5.1.2. Market Forecast, 2022 - 2030
8.2.13.5.2. Europe
8.2.13.5.2.1. Market Estimation, 2015 - 2021
8.2.13.5.2.2. Market Forecast, 2022 - 2030
8.2.13.5.3. Asia Pacific
8.2.13.5.3.1. Market Estimation, 2015 - 2021
8.2.13.5.3.2. Market Forecast, 2022 - 2030
8.2.13.5.4. Middle East and Africa
8.2.13.5.4.1. Market Estimation, 2015 - 2021
8.2.13.5.4.2. Market Forecast, 2022 - 2030
8.2.13.5.5. Latin America
8.2.13.5.5.1. Market Estimation, 2015 - 2021
8.2.13.5.5.2. Market Forecast, 2022 - 2030
8.2.14. Others
8.2.14.1. Definition
8.2.14.2. Market Estimation and Penetration, 2015 -
2021
8.2.14.3. Market Forecast, 2022 - 2030
8.2.14.4. Compound Annual Growth Rate (CAGR)
8.2.14.5. Regional Bifurcation
8.2.14.5.1. North America
8.2.14.5.1.1. Market Estimation, 2015 - 2021
8.2.14.5.1.2. Market Forecast, 2022 - 2030
8.2.14.5.2. Europe
8.2.14.5.2.1. Market Estimation, 2015 - 2021
8.2.14.5.2.2. Market Forecast, 2022 - 2030
8.2.14.5.3. Asia Pacific
8.2.14.5.3.1. Market Estimation, 2015 - 2021
8.2.14.5.3.2. Market Forecast, 2022 - 2030
8.2.14.5.4. Middle East and Africa
8.2.14.5.4.1. Market Estimation, 2015 - 2021
8.2.14.5.4.2. Market Forecast, 2022 - 2030
8.2.14.5.5. Latin America
8.2.14.5.5.1. Market Estimation, 2015 - 2021
8.2.14.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Product
9.
Global Point of Care (PoC) Testing Market Analysis
and Forecasts, 2022 - 2030
9.1. Overview
9.2. Global
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
9.2.1. Prescription Based
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Over The Counter (OTC)
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Type
10. Global
Point of Care (PoC) Testing Market Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
10.2.1. Hospitals (Definition, Market Estimation and
Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast
(2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North
America, Europe, Asia Pacific, Middle East and Africa, Latin America) and
Information on Critical Care Units, Neonatal Intensive Care Unit (NICU),
Others)
10.2.1.1. Critical Care Units
10.2.1.2. Neonatal Intensive Care Unit (NICU)
10.2.1.3. Others
10.2.2. Private Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Diagnostic Centres
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.2.4. Home Care Settings
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 -
2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 - 2030
10.2.5. Ambulatory Care Centers
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 -
2021
10.2.5.3. Market Forecast, 2022 - 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2021
10.2.5.5.1.2. Market Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2021
10.2.5.5.2.2. Market Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2021
10.2.5.5.3.2. Market Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2021
10.2.5.5.4.2. Market Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2021
10.2.5.5.5.2. Market Forecast, 2022 - 2030
10.2.6. Emergency Departments
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 -
2021
10.2.6.3. Market Forecast, 2022 - 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 - 2021
10.2.6.5.1.2. Market Forecast, 2022 - 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2021
10.2.6.5.2.2. Market Forecast, 2022 - 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2021
10.2.6.5.3.2. Market Forecast, 2022 - 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2021
10.2.6.5.4.2. Market Forecast, 2022 - 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 - 2021
10.2.6.5.5.2. Market Forecast, 2022 - 2030
10.2.7. Laboratories
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 -
2021
10.2.7.3. Market Forecast, 2022 - 2030
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 - 2021
10.2.7.5.1.2. Market Forecast, 2022 - 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2021
10.2.7.5.2.2. Market Forecast, 2022 - 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2021
10.2.7.5.3.2. Market Forecast, 2022 - 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2021
10.2.7.5.4.2. Market Forecast, 2022 - 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 - 2021
10.2.7.5.5.2. Market Forecast, 2022 - 2030
10.2.8. Others
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2015 -
2021
10.2.8.3. Market Forecast, 2022 - 2030
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2015 - 2021
10.2.8.5.1.2. Market Forecast, 2022 - 2030
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2015 - 2021
10.2.8.5.2.2. Market Forecast, 2022 - 2030
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2015 - 2021
10.2.8.5.3.2. Market Forecast, 2022 - 2030
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 - 2021
10.2.8.5.4.2. Market Forecast, 2022 - 2030
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2015 - 2021
10.2.8.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End-user
11. North America Point of Care (PoC) Testing Market Analysis
and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America
Point of Care (PoC) Testing Market Revenue (US$ Mn)
11.2. North America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
11.2.1. Glucose monitoring
11.2.2. Cardiometabolic Monitoring
11.2.3. Albumin Testing
11.2.4. Infectious disease testing
11.2.4.1. HIV Infections
11.2.4.2. Malaria
11.2.4.3. Syphilis
11.2.4.4. E.Coli
11.2.4.5. Influenza
11.2.4.6. Others
11.2.5. Coagulation monitoring
11.2.6. Pregnancy and fertility testing
11.2.7. Cancer marker testing
11.2.8. Urine analysis testing
11.2.9. Cholesterol testing
11.2.10. Hematology testing
11.2.11. Drugs-of-abuse testing
11.2.12. Fecal Occult testing
11.2.13. Covid-19 testing
11.2.14. Others
11.3. North America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
11.3.1. Prescription Based
11.3.2. Over The Counter (OTC)
11.4. North America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
11.4.1. Hospitals
11.4.1.1. Critical Care Units
11.4.1.2. Neonatal Intensive Care Unit (NICU)
11.4.1.3. Others
11.4.2. Private Clinics
11.4.3. Diagnostic Centres
11.4.4. Home Care Settings
11.4.5. Ambulatory Care Centers
11.4.6. Emergency Departments
11.4.7. Laboratories
11.4.8. Others
11.5. North America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
11.5.1.1.1. Glucose monitoring
11.5.1.1.2. Cardiometabolic Monitoring
11.5.1.1.3. Albumin Testing
11.5.1.1.4. Infectious disease testing
11.5.1.1.4.1. HIV Infections
11.5.1.1.4.2. Malaria
11.5.1.1.4.3. Syphilis
11.5.1.1.4.4. E.Coli
11.5.1.1.4.5. Influenza
11.5.1.1.4.6. Others
11.5.1.1.5. Coagulation monitoring
11.5.1.1.6. Pregnancy and fertility testing
11.5.1.1.7. Cancer marker testing
11.5.1.1.8. Urine analysis testing
11.5.1.1.9. Cholesterol testing
11.5.1.1.10. Hematology testing
11.5.1.1.11. Drugs-of-abuse testing
11.5.1.1.12. Fecal Occult testing
11.5.1.1.13. Covid-19 testing
11.5.1.1.14. Others
11.5.1.2. U.S
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.1.2.1. Prescription Based
11.5.1.2.2. Over The Counter (OTC)
11.5.1.3. U.S
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
11.5.1.3.1. Hospitals
11.5.1.3.1.1. Critical Care Units
11.5.1.3.1.2. Neonatal Intensive Care Unit (NICU)
11.5.1.3.1.3. Others
11.5.1.3.2. Private Clinics
11.5.1.3.3. Diagnostic Centres
11.5.1.3.4. Home Care Settings
11.5.1.3.5. Ambulatory Care Centers
11.5.1.3.6. Emergency Departments
11.5.1.3.7. Laboratories
11.5.1.3.8. Others
11.5.2. Canada
11.5.2.1. Canada
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
11.5.2.1.1. Glucose monitoring
11.5.2.1.2. Cardiometabolic Monitoring
11.5.2.1.3. Albumin Testing
11.5.2.1.4. Infectious disease testing
11.5.2.1.4.1. HIV Infections
11.5.2.1.4.2. Malaria
11.5.2.1.4.3. Syphilis
11.5.2.1.4.4. E.Coli
11.5.2.1.4.5. Influenza
11.5.2.1.4.6. Others
11.5.2.1.5. Coagulation monitoring
11.5.2.1.6. Pregnancy and fertility testing
11.5.2.1.7. Cancer marker testing
11.5.2.1.8. Urine analysis testing
11.5.2.1.9. Cholesterol testing
11.5.2.1.10. Hematology testing
11.5.2.1.11. Drugs-of-abuse testing
11.5.2.1.12. Fecal Occult testing
11.5.2.1.13. Covid-19 testing
11.5.2.1.14. Others
11.5.2.2. Canada
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.2.2.1. Prescription Based
11.5.2.2.2. Over The Counter (OTC)
11.5.2.3. Canada
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
11.5.2.3.1. Hospitals
11.5.2.3.1.1. Critical Care Units
11.5.2.3.1.2. Neonatal Intensive Care Unit (NICU)
11.5.2.3.1.3. Others
11.5.2.3.2. Private Clinics
11.5.2.3.3. Diagnostic Centres
11.5.2.3.4. Home Care Settings
11.5.2.3.5. Ambulatory Care Centers
11.5.2.3.6. Emergency Departments
11.5.2.3.7. Laboratories
11.5.2.3.8. Others
11.5.3. Mexico
11.5.3.1. Mexico
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
11.5.3.1.1. Glucose monitoring
11.5.3.1.2. Cardiometabolic Monitoring
11.5.3.1.3. Albumin Testing
11.5.3.1.4. Infectious disease testing
11.5.3.1.4.1. HIV Infections
11.5.3.1.4.2. Malaria
11.5.3.1.4.3. Syphilis
11.5.3.1.4.4. E.Coli
11.5.3.1.4.5. Influenza
11.5.3.1.4.6. Others
11.5.3.1.5. Coagulation monitoring
11.5.3.1.6. Pregnancy and fertility testing
11.5.3.1.7. Cancer marker testing
11.5.3.1.8. Urine analysis testing
11.5.3.1.9. Cholesterol testing
11.5.3.1.10. Hematology testing
11.5.3.1.11. Drugs-of-abuse testing
11.5.3.1.12. Fecal Occult testing
11.5.3.1.13. Covid-19 testing
11.5.3.1.14. Others
11.5.3.2. Mexico
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.3.2.1. Prescription
Based
11.5.3.2.2. Over The Counter (OTC)
11.5.3.3. Mexico
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
11.5.3.3.1. Hospitals
11.5.3.3.1.1. Critical Care Units
11.5.3.3.1.2. Neonatal Intensive Care Unit (NICU)
11.5.3.3.1.3. Others
11.5.3.3.2. Private Clinics
11.5.3.3.3. Diagnostic Centres
11.5.3.3.4. Home Care Settings
11.5.3.3.5. Ambulatory Care Centers
11.5.3.3.6. Emergency Departments
11.5.3.3.7. Laboratories
11.5.3.3.8. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
11.5.4.1.1. Glucose monitoring
11.5.4.1.2. Cardiometabolic Monitoring
11.5.4.1.3. Albumin Testing
11.5.4.1.4. Infectious disease testing
11.5.4.1.4.1. HIV Infections
11.5.4.1.4.2. Malaria
11.5.4.1.4.3. Syphilis
11.5.4.1.4.4. E.Coli
11.5.4.1.4.5. Influenza
11.5.4.1.4.6. Others
11.5.4.1.5. Coagulation monitoring
11.5.4.1.6. Pregnancy and fertility testing
11.5.4.1.7. Cancer marker testing
11.5.4.1.8. Urine analysis testing
11.5.4.1.9. Cholesterol testing
11.5.4.1.10. Hematology testing
11.5.4.1.11. Drugs-of-abuse testing
11.5.4.1.12. Fecal Occult testing
11.5.4.1.13. Covid-19 testing
11.5.4.1.14. Others
11.5.4.2. Rest of North America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.4.2.1. Prescription Based
11.5.4.2.2. Over The Counter (OTC)
11.5.4.3. Rest of North America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
11.5.4.3.1. Hospitals
11.5.4.3.1.1. Critical Care Units
11.5.4.3.1.2. Neonatal Intensive Care Unit (NICU)
11.5.4.3.1.3. Others
11.5.4.3.2. Private Clinics
11.5.4.3.3. Diagnostic Centres
11.5.4.3.4. Home Care Settings
11.5.4.3.5. Ambulatory Care Centers
11.5.4.3.6. Emergency Departments
11.5.4.3.7. Laboratories
11.5.4.3.8. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Product
11.6.3. By Type
11.6.4. By End-user
12. Europe
Point of Care (PoC) Testing Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe
Point of Care (PoC) Testing Market Revenue (US$ Mn)
12.2. Europe
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.2.1. Glucose monitoring
12.2.2. Cardiometabolic Monitoring
12.2.3. Albumin Testing
12.2.4. Infectious disease testing
12.2.4.1. HIV Infections
12.2.4.2. Malaria
12.2.4.3. Syphilis
12.2.4.4. E.Coli
12.2.4.5. Influenza
12.2.4.6. Others
12.2.5. Coagulation monitoring
12.2.6. Pregnancy and fertility testing
12.2.7. Cancer marker testing
12.2.8. Urine analysis testing
12.2.9. Cholesterol testing
12.2.10. Hematology testing
12.2.11. Drugs-of-abuse testing
12.2.12. Fecal Occult testing
12.2.13. Covid-19 testing
12.2.14. Others
12.3. Europe
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.3.1. Prescription Based
12.3.2. Over The Counter (OTC)
12.4. Europe
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.4.1. Hospitals
12.4.1.1. Critical Care Units
12.4.1.2. Neonatal Intensive Care Unit (NICU)
12.4.1.3. Others
12.4.2. Private Clinics
12.4.3. Diagnostic Centres
12.4.4. Home Care Settings
12.4.5. Ambulatory Care Centers
12.4.6. Emergency Departments
12.4.7. Laboratories
12.4.8. Others
12.5. Europe
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.1. France
12.5.1.1. France
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.1.1.1. Glucose monitoring
12.5.1.1.2. Cardiometabolic Monitoring
12.5.1.1.3. Albumin Testing
12.5.1.1.4. Infectious disease testing
12.5.1.1.4.1. HIV Infections
12.5.1.1.4.2. Malaria
12.5.1.1.4.3. Syphilis
12.5.1.1.4.4. E.Coli
12.5.1.1.4.5. Influenza
12.5.1.1.4.6. Others
12.5.1.1.5. Coagulation monitoring
12.5.1.1.6. Pregnancy and fertility testing
12.5.1.1.7. Cancer marker testing
12.5.1.1.8. Urine analysis testing
12.5.1.1.9. Cholesterol testing
12.5.1.1.10. Hematology testing
12.5.1.1.11. Drugs-of-abuse testing
12.5.1.1.12. Fecal Occult testing
12.5.1.1.13. Covid-19 testing
12.5.1.1.14. Others
12.5.1.2. France
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.1.2.1. Prescription Based
12.5.1.2.2. Over The Counter (OTC)
12.5.1.3. France
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.1.3.1. Hospitals
12.5.1.3.1.1. Critical Care Units
12.5.1.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.1.3.1.3. Others
12.5.1.3.2. Private Clinics
12.5.1.3.3. Diagnostic Centres
12.5.1.3.4. Home Care Settings
12.5.1.3.5. Ambulatory Care Centers
12.5.1.3.6. Emergency Departments
12.5.1.3.7. Laboratories
12.5.1.3.8. Others
12.5.2. The UK
12.5.2.1. The UK
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.2.1.1. Glucose monitoring
12.5.2.1.2. Cardiometabolic Monitoring
12.5.2.1.3. Albumin Testing
12.5.2.1.4. Infectious disease testing
12.5.2.1.4.1. HIV Infections
12.5.2.1.4.2. Malaria
12.5.2.1.4.3. Syphilis
12.5.2.1.4.4. E.Coli
12.5.2.1.4.5. Influenza
12.5.2.1.4.6. Others
12.5.2.1.5. Coagulation monitoring
12.5.2.1.6. Pregnancy and fertility testing
12.5.2.1.7. Cancer marker testing
12.5.2.1.8. Urine analysis testing
12.5.2.1.9. Cholesterol testing
12.5.2.1.10. Hematology testing
12.5.2.1.11. Drugs-of-abuse testing
12.5.2.1.12. Fecal Occult testing
12.5.2.1.13. Covid-19 testing
12.5.2.1.14. Others
12.5.2.2. The UK
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.2.2.1. Prescription Based
12.5.2.2.2. Over The Counter (OTC)
12.5.2.3. The UK
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.2.3.1. Hospitals
12.5.2.3.1.1. Critical Care Units
12.5.2.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.2.3.1.3. Others
12.5.2.3.2. Private Clinics
12.5.2.3.3. Diagnostic Centres
12.5.2.3.4. Home Care Settings
12.5.2.3.5. Ambulatory Care Centers
12.5.2.3.6. Emergency Departments
12.5.2.3.7. Laboratories
12.5.2.3.8. Others
12.5.3. Spain
12.5.3.1. Spain
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.3.1.1. Glucose monitoring
12.5.3.1.2. Cardiometabolic Monitoring
12.5.3.1.3. Albumin Testing
12.5.3.1.4. Infectious disease testing
12.5.3.1.4.1. HIV Infections
12.5.3.1.4.2. Malaria
12.5.3.1.4.3. Syphilis
12.5.3.1.4.4. E.Coli
12.5.3.1.4.5. Influenza
12.5.3.1.4.6. Others
12.5.3.1.5. Coagulation monitoring
12.5.3.1.6. Pregnancy and fertility testing
12.5.3.1.7. Cancer marker testing
12.5.3.1.8. Urine analysis testing
12.5.3.1.9. Cholesterol testing
12.5.3.1.10. Hematology testing
12.5.3.1.11. Drugs-of-abuse testing
12.5.3.1.12. Fecal Occult testing
12.5.3.1.13. Covid-19 testing
12.5.3.1.14. Others
12.5.3.2. Spain
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.3.2.1. Prescription Based
12.5.3.2.2. Over The Counter (OTC)
12.5.3.3. Spain
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.3.3.1. Hospitals
12.5.3.3.1.1. Critical Care Units
12.5.3.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.3.3.1.3. Others
12.5.3.3.2. Private Clinics
12.5.3.3.3. Diagnostic Centres
12.5.3.3.4. Home Care Settings
12.5.3.3.5. Ambulatory Care Centers
12.5.3.3.6. Emergency Departments
12.5.3.3.7. Laboratories
12.5.3.3.8. Others
12.5.4. Germany
12.5.4.1. Germany
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.4.1.1. Glucose monitoring
12.5.4.1.2. Cardiometabolic Monitoring
12.5.4.1.3. Albumin Testing
12.5.4.1.4. Infectious disease testing
12.5.4.1.4.1. HIV Infections
12.5.4.1.4.2. Malaria
12.5.4.1.4.3. Syphilis
12.5.4.1.4.4. E.Coli
12.5.4.1.4.5. Influenza
12.5.4.1.4.6. Others
12.5.4.1.5. Coagulation monitoring
12.5.4.1.6. Pregnancy and fertility testing
12.5.4.1.7. Cancer marker testing
12.5.4.1.8. Urine analysis testing
12.5.4.1.9. Cholesterol testing
12.5.4.1.10. Hematology testing
12.5.4.1.11. Drugs-of-abuse testing
12.5.4.1.12. Fecal Occult testing
12.5.4.1.13. Covid-19 testing
12.5.4.1.14. Others
12.5.4.2. Germany
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.4.2.1. Prescription Based
12.5.4.2.2. Over The Counter (OTC)
12.5.4.3. Germany
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.4.3.1. Hospitals
12.5.4.3.1.1. Critical Care Units
12.5.4.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.4.3.1.3. Others
12.5.4.3.2. Private Clinics
12.5.4.3.3. Diagnostic Centres
12.5.4.3.4. Home Care Settings
12.5.4.3.5. Ambulatory Care Centers
12.5.4.3.6. Emergency Departments
12.5.4.3.7. Laboratories
12.5.4.3.8. Others
12.5.5. Italy
12.5.5.1. Italy
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.5.1.1. Glucose monitoring
12.5.5.1.2. Cardiometabolic Monitoring
12.5.5.1.3. Albumin Testing
12.5.5.1.4. Infectious disease testing
12.5.5.1.4.1. HIV Infections
12.5.5.1.4.2. Malaria
12.5.5.1.4.3. Syphilis
12.5.5.1.4.4. E.Coli
12.5.5.1.4.5. Influenza
12.5.5.1.4.6. Others
12.5.5.1.5. Coagulation monitoring
12.5.5.1.6. Pregnancy and fertility testing
12.5.5.1.7. Cancer marker testing
12.5.5.1.8. Urine analysis testing
12.5.5.1.9. Cholesterol testing
12.5.5.1.10. Hematology testing
12.5.5.1.11. Drugs-of-abuse testing
12.5.5.1.12. Fecal Occult testing
12.5.5.1.13. Covid-19 testing
12.5.5.1.14. Others
12.5.5.2. Italy
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.5.2.1. Prescription Based
12.5.5.2.2. Over The Counter (OTC)
12.5.5.3. Italy
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.5.3.1. Hospitals
12.5.5.3.1.1. Critical Care Units
12.5.5.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.5.3.1.3. Others
12.5.5.3.2. Private Clinics
12.5.5.3.3. Diagnostic Centres
12.5.5.3.4. Home Care Settings
12.5.5.3.5. Ambulatory Care Centers
12.5.5.3.6. Emergency Departments
12.5.5.3.7. Laboratories
12.5.5.3.8. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
12.5.6.1.1. Glucose monitoring
12.5.6.1.2. Cardiometabolic Monitoring
12.5.6.1.3. Albumin Testing
12.5.6.1.4. Infectious disease testing
12.5.6.1.4.1. HIV Infections
12.5.6.1.4.2. Malaria
12.5.6.1.4.3. Syphilis
12.5.6.1.4.4. E.Coli
12.5.6.1.4.5. Influenza
12.5.6.1.4.6. Others
12.5.6.1.5. Coagulation monitoring
12.5.6.1.6. Pregnancy and fertility testing
12.5.6.1.7. Cancer marker testing
12.5.6.1.8. Urine analysis testing
12.5.6.1.9. Cholesterol testing
12.5.6.1.10. Hematology testing
12.5.6.1.11. Drugs-of-abuse testing
12.5.6.1.12. Fecal Occult testing
12.5.6.1.13. Covid-19 testing
12.5.6.1.14. Others
12.5.6.2. Nordic Countries Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.6.2.1. Prescription Based
12.5.6.2.2. Over The Counter (OTC)
12.5.6.3. Nordic Countries Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
12.5.6.3.1. Hospitals
12.5.6.3.1.1. Critical Care Units
12.5.6.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.6.3.1.3. Others
12.5.6.3.2. Private Clinics
12.5.6.3.3. Diagnostic Centres
12.5.6.3.4. Home Care Settings
12.5.6.3.5. Ambulatory Care Centers
12.5.6.3.6. Emergency Departments
12.5.6.3.7. Laboratories
12.5.6.3.8. Others
12.5.6.4. Nordic Countries Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
12.5.7.1.1. Glucose monitoring
12.5.7.1.2. Cardiometabolic Monitoring
12.5.7.1.3. Albumin Testing
12.5.7.1.4. Infectious disease testing
12.5.7.1.4.1. HIV Infections
12.5.7.1.4.2. Malaria
12.5.7.1.4.3. Syphilis
12.5.7.1.4.4. E.Coli
12.5.7.1.4.5. Influenza
12.5.7.1.4.6. Others
12.5.7.1.5. Coagulation monitoring
12.5.7.1.6. Pregnancy and fertility testing
12.5.7.1.7. Cancer marker testing
12.5.7.1.8. Urine analysis testing
12.5.7.1.9. Cholesterol testing
12.5.7.1.10. Hematology testing
12.5.7.1.11. Drugs-of-abuse testing
12.5.7.1.12. Fecal Occult testing
12.5.7.1.13. Covid-19 testing
12.5.7.1.14. Others
12.5.7.2. Benelux Union
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.7.2.1. Prescription Based
12.5.7.2.2. Over The Counter (OTC)
12.5.7.3. Benelux Union
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
12.5.7.3.1. Hospitals
12.5.7.3.1.1. Critical Care Units
12.5.7.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.7.3.1.3. Others
12.5.7.3.2. Private Clinics
12.5.7.3.3. Diagnostic Centres
12.5.7.3.4. Home Care Settings
12.5.7.3.5. Ambulatory Care Centers
12.5.7.3.6. Emergency Departments
12.5.7.3.7. Laboratories
12.5.7.3.8. Others
12.5.7.4. Benelux Union
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
12.5.8.1.1. Glucose monitoring
12.5.8.1.2. Cardiometabolic Monitoring
12.5.8.1.3. Albumin Testing
12.5.8.1.4. Infectious disease testing
12.5.8.1.4.1. HIV Infections
12.5.8.1.4.2. Malaria
12.5.8.1.4.3. Syphilis
12.5.8.1.4.4. E.Coli
12.5.8.1.4.5. Influenza
12.5.8.1.4.6. Others
12.5.8.1.5. Coagulation monitoring
12.5.8.1.6. Pregnancy and fertility testing
12.5.8.1.7. Cancer marker testing
12.5.8.1.8. Urine analysis testing
12.5.8.1.9. Cholesterol testing
12.5.8.1.10. Hematology testing
12.5.8.1.11. Drugs-of-abuse testing
12.5.8.1.12. Fecal Occult testing
12.5.8.1.13. Covid-19 testing
12.5.8.1.14. Others
12.5.8.2. Rest of Europe Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.8.2.1. Prescription Based
12.5.8.2.2. Over The Counter (OTC)
12.5.8.3. Rest of Europe Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
12.5.8.3.1. Hospitals
12.5.8.3.1.1. Critical Care Units
12.5.8.3.1.2. Neonatal Intensive Care Unit (NICU)
12.5.8.3.1.3. Others
12.5.8.3.2. Private Clinics
12.5.8.3.3. Diagnostic Centres
12.5.8.3.4. Home Care Settings
12.5.8.3.5. Ambulatory Care Centers
12.5.8.3.6. Emergency Departments
12.5.8.3.7. Laboratories
12.5.8.3.8. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Product
12.6.3. By Type
12.6.4. By End-user
13. Asia Pacific
Point of Care (PoC) Testing Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific
Point of Care (PoC) Testing Market Revenue (US$ Mn)
13.2. Asia Pacific
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.2.1. Glucose monitoring
13.2.2. Cardiometabolic Monitoring
13.2.3. Albumin Testing
13.2.4. Infectious disease testing
13.2.4.1. HIV Infections
13.2.4.2. Malaria
13.2.4.3. Syphilis
13.2.4.4. E.Coli
13.2.4.5. Influenza
13.2.4.6. Others
13.2.5. Coagulation monitoring
13.2.6. Pregnancy and fertility testing
13.2.7. Cancer marker testing
13.2.8. Urine analysis testing
13.2.9. Cholesterol testing
13.2.10. Hematology testing
13.2.11. Drugs-of-abuse testing
13.2.12. Fecal Occult testing
13.2.13. Covid-19 testing
13.2.14. Others
13.3. Asia Pacific
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.3.1. Prescription Based
13.3.2. Over The Counter (OTC)
13.4. Asia Pacific
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.4.1. Hospitals
13.4.1.1. Critical Care Units
13.4.1.2. Neonatal Intensive Care Unit (NICU)
13.4.1.3. Others
13.4.2. Private Clinics
13.4.3. Diagnostic Centres
13.4.4. Home Care Settings
13.4.5. Ambulatory Care Centers
13.4.6. Emergency Departments
13.4.7. Laboratories
13.4.8. Others
13.5. Asia Pacific
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.1.1.1. Glucose monitoring
13.5.1.1.2. Cardiometabolic Monitoring
13.5.1.1.3. Albumin Testing
13.5.1.1.4. Infectious disease testing
13.5.1.1.4.1. HIV Infections
13.5.1.1.4.2. Malaria
13.5.1.1.4.3. Syphilis
13.5.1.1.4.4. E.Coli
13.5.1.1.4.5. Influenza
13.5.1.1.4.6. Others
13.5.1.1.5. Coagulation monitoring
13.5.1.1.6. Pregnancy and fertility testing
13.5.1.1.7. Cancer marker testing
13.5.1.1.8. Urine analysis testing
13.5.1.1.9. Cholesterol testing
13.5.1.1.10. Hematology testing
13.5.1.1.11. Drugs-of-abuse testing
13.5.1.1.12. Fecal Occult testing
13.5.1.1.13. Covid-19 testing
13.5.1.1.14. Others
13.5.1.2. China
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.1.2.1. Prescription Based
13.5.1.2.2. Over The Counter (OTC)
13.5.1.3. China
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.1.3.1. Hospitals
13.5.1.3.1.1. Critical Care Units
13.5.1.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.1.3.1.3. Others
13.5.1.3.2. Private Clinics
13.5.1.3.3. Diagnostic Centres
13.5.1.3.4. Home Care Settings
13.5.1.3.5. Ambulatory Care Centers
13.5.1.3.6. Emergency Departments
13.5.1.3.7. Laboratories
13.5.1.3.8. Others
13.5.2. Japan
13.5.2.1. Japan
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.2.1.1. Glucose monitoring
13.5.2.1.2. Cardiometabolic Monitoring
13.5.2.1.3. Albumin Testing
13.5.2.1.4. Infectious disease testing
13.5.2.1.4.1. HIV Infections
13.5.2.1.4.2. Malaria
13.5.2.1.4.3. Syphilis
13.5.2.1.4.4. E.Coli
13.5.2.1.4.5. Influenza
13.5.2.1.4.6. Others
13.5.2.1.5. Coagulation monitoring
13.5.2.1.6. Pregnancy and fertility testing
13.5.2.1.7. Cancer marker testing
13.5.2.1.8. Urine analysis testing
13.5.2.1.9. Cholesterol testing
13.5.2.1.10. Hematology testing
13.5.2.1.11. Drugs-of-abuse testing
13.5.2.1.12. Fecal Occult testing
13.5.2.1.13. Covid-19 testing
13.5.2.1.14. Others
13.5.2.2. Japan
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.2.2.1. Prescription Based
13.5.2.2.2. Over The Counter (OTC)
13.5.2.3. Japan
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.2.3.1. Hospitals
13.5.2.3.1.1. Critical Care Units
13.5.2.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.2.3.1.3. Others
13.5.2.3.2. Private Clinics
13.5.2.3.3. Diagnostic Centres
13.5.2.3.4. Home Care Settings
13.5.2.3.5. Ambulatory Care Centers
13.5.2.3.6. Emergency Departments
13.5.2.3.7. Laboratories
13.5.2.3.8. Others
13.5.3. India
13.5.3.1. India
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.3.1.1. Glucose monitoring
13.5.3.1.2. Cardiometabolic Monitoring
13.5.3.1.3. Albumin Testing
13.5.3.1.4. Infectious disease testing
13.5.3.1.4.1. HIV Infections
13.5.3.1.4.2. Malaria
13.5.3.1.4.3. Syphilis
13.5.3.1.4.4. E.Coli
13.5.3.1.4.5. Influenza
13.5.3.1.4.6. Others
13.5.3.1.5. Coagulation monitoring
13.5.3.1.6. Pregnancy and fertility testing
13.5.3.1.7. Cancer marker testing
13.5.3.1.8. Urine analysis testing
13.5.3.1.9. Cholesterol testing
13.5.3.1.10. Hematology testing
13.5.3.1.11. Drugs-of-abuse testing
13.5.3.1.12. Fecal Occult testing
13.5.3.1.13. Covid-19 testing
13.5.3.1.14. Others
13.5.3.2. India
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.3.2.1. Prescription Based
13.5.3.2.2. Over The Counter (OTC)
13.5.3.3. India
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.3.3.1. Hospitals
13.5.3.3.1.1. Critical Care Units
13.5.3.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.3.3.1.3. Others
13.5.3.3.2. Private Clinics
13.5.3.3.3. Diagnostic Centres
13.5.3.3.4. Home Care Settings
13.5.3.3.5. Ambulatory Care Centers
13.5.3.3.6. Emergency Departments
13.5.3.3.7. Laboratories
13.5.3.3.8. Others
13.5.4. New Zealand
13.5.4.1. New Zealand
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.4.1.1. Glucose monitoring
13.5.4.1.2. Cardiometabolic Monitoring
13.5.4.1.3. Albumin Testing
13.5.4.1.4. Infectious disease testing
13.5.4.1.4.1. HIV Infections
13.5.4.1.4.2. Malaria
13.5.4.1.4.3. Syphilis
13.5.4.1.4.4. E.Coli
13.5.4.1.4.5. Influenza
13.5.4.1.4.6. Others
13.5.4.1.5. Coagulation monitoring
13.5.4.1.6. Pregnancy and fertility testing
13.5.4.1.7. Cancer marker testing
13.5.4.1.8. Urine analysis testing
13.5.4.1.9. Cholesterol testing
13.5.4.1.10. Hematology testing
13.5.4.1.11. Drugs-of-abuse testing
13.5.4.1.12. Fecal Occult testing
13.5.4.1.13. Covid-19 testing
13.5.4.1.14. Others
13.5.4.2. New Zealand
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.4.2.1. Prescription Based
13.5.4.2.2. Over The Counter (OTC)
13.5.4.3. New Zealand
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.4.3.1. Hospitals
13.5.4.3.1.1. Critical Care Units
13.5.4.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.4.3.1.3. Others
13.5.4.3.2. Private Clinics
13.5.4.3.3. Diagnostic Centres
13.5.4.3.4. Home Care Settings
13.5.4.3.5. Ambulatory Care Centers
13.5.4.3.6. Emergency Departments
13.5.4.3.7. Laboratories
13.5.4.3.8. Others
13.5.5. Australia
13.5.5.1. Australia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.5.1.1. Glucose monitoring
13.5.5.1.2. Cardiometabolic Monitoring
13.5.5.1.3. Albumin Testing
13.5.5.1.4. Infectious disease testing
13.5.5.1.4.1. HIV Infections
13.5.5.1.4.2. Malaria
13.5.5.1.4.3. Syphilis
13.5.5.1.4.4. E.Coli
13.5.5.1.4.5. Influenza
13.5.5.1.4.6. Others
13.5.5.1.5. Coagulation monitoring
13.5.5.1.6. Pregnancy and fertility testing
13.5.5.1.7. Cancer marker testing
13.5.5.1.8. Urine analysis testing
13.5.5.1.9. Cholesterol testing
13.5.5.1.10. Hematology testing
13.5.5.1.11. Drugs-of-abuse testing
13.5.5.1.12. Fecal Occult testing
13.5.5.1.13. Covid-19 testing
13.5.5.1.14. Others
13.5.5.2. Australia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.5.2.1. Prescription Based
13.5.5.2.2. Over The Counter (OTC)
13.5.5.3. Australia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.5.3.1. Hospitals
13.5.5.3.1.1. Critical Care Units
13.5.5.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.5.3.1.3. Others
13.5.5.3.2. Private Clinics
13.5.5.3.3. Diagnostic Centres
13.5.5.3.4. Home Care Settings
13.5.5.3.5. Ambulatory Care Centers
13.5.5.3.6. Emergency Departments
13.5.5.3.7. Laboratories
13.5.5.3.8. Others
13.5.6. South Korea
13.5.6.1. South Korea
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
13.5.6.1.1. Glucose monitoring
13.5.6.1.2. Cardiometabolic Monitoring
13.5.6.1.3. Albumin Testing
13.5.6.1.4. Infectious disease testing
13.5.6.1.4.1. HIV Infections
13.5.6.1.4.2. Malaria
13.5.6.1.4.3. Syphilis
13.5.6.1.4.4. E.Coli
13.5.6.1.4.5. Influenza
13.5.6.1.4.6. Others
13.5.6.1.5. Coagulation monitoring
13.5.6.1.6. Pregnancy and fertility testing
13.5.6.1.7. Cancer marker testing
13.5.6.1.8. Urine analysis testing
13.5.6.1.9. Cholesterol testing
13.5.6.1.10. Hematology testing
13.5.6.1.11. Drugs-of-abuse testing
13.5.6.1.12. Fecal Occult testing
13.5.6.1.13. Covid-19 testing
13.5.6.1.14. Others
13.5.6.2. South Korea
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.6.2.1. Prescription Based
13.5.6.2.2. Over The Counter (OTC)
13.5.6.3. South Korea
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
13.5.6.3.1. Hospitals
13.5.6.3.1.1. Critical Care Units
13.5.6.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.6.3.1.3. Others
13.5.6.3.2. Private Clinics
13.5.6.3.3. Diagnostic Centres
13.5.6.3.4. Home Care Settings
13.5.6.3.5. Ambulatory Care Centers
13.5.6.3.6. Emergency Departments
13.5.6.3.7. Laboratories
13.5.6.3.8. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
13.5.7.1.1. Glucose monitoring
13.5.7.1.2. Cardiometabolic Monitoring
13.5.7.1.3. Albumin Testing
13.5.7.1.4. Infectious disease testing
13.5.7.1.4.1. HIV Infections
13.5.7.1.4.2. Malaria
13.5.7.1.4.3. Syphilis
13.5.7.1.4.4. E.Coli
13.5.7.1.4.5. Influenza
13.5.7.1.4.6. Others
13.5.7.1.5. Coagulation monitoring
13.5.7.1.6. Pregnancy and fertility testing
13.5.7.1.7. Cancer marker testing
13.5.7.1.8. Urine analysis testing
13.5.7.1.9. Cholesterol testing
13.5.7.1.10. Hematology testing
13.5.7.1.11. Drugs-of-abuse testing
13.5.7.1.12. Fecal Occult testing
13.5.7.1.13. Covid-19 testing
13.5.7.1.14. Others
13.5.7.2. Southeast Asia Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.7.2.1. Prescription Based
13.5.7.2.2. Over The Counter (OTC)
13.5.7.3. Southeast Asia Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
13.5.7.3.1. Hospitals
13.5.7.3.1.1. Critical Care Units
13.5.7.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.7.3.1.3. Others
13.5.7.3.2. Private Clinics
13.5.7.3.3. Diagnostic Centres
13.5.7.3.4. Home Care Settings
13.5.7.3.5. Ambulatory Care Centers
13.5.7.3.6. Emergency Departments
13.5.7.3.7. Laboratories
13.5.7.3.8. Others
13.5.7.4. Southeast Asia Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
13.5.8.1.1. Glucose monitoring
13.5.8.1.2. Cardiometabolic Monitoring
13.5.8.1.3. Albumin Testing
13.5.8.1.4. Infectious disease testing
13.5.8.1.4.1. HIV Infections
13.5.8.1.4.2. Malaria
13.5.8.1.4.3. Syphilis
13.5.8.1.4.4. E.Coli
13.5.8.1.4.5. Influenza
13.5.8.1.4.6. Others
13.5.8.1.5. Coagulation monitoring
13.5.8.1.6. Pregnancy and fertility testing
13.5.8.1.7. Cancer marker testing
13.5.8.1.8. Urine analysis testing
13.5.8.1.9. Cholesterol testing
13.5.8.1.10. Hematology testing
13.5.8.1.11. Drugs-of-abuse testing
13.5.8.1.12. Fecal Occult testing
13.5.8.1.13. Covid-19 testing
13.5.8.1.14. Others
13.5.8.2. Rest of Asia Pacific Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.8.2.1. Prescription Based
13.5.8.2.2. Over The Counter (OTC)
13.5.8.3. Rest of Asia Pacific Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
13.5.8.3.1. Hospitals
13.5.8.3.1.1. Critical Care Units
13.5.8.3.1.2. Neonatal Intensive Care Unit (NICU)
13.5.8.3.1.3. Others
13.5.8.3.2. Private Clinics
13.5.8.3.3. Diagnostic Centres
13.5.8.3.4. Home Care Settings
13.5.8.3.5. Ambulatory Care Centers
13.5.8.3.6. Emergency Departments
13.5.8.3.7. Laboratories
13.5.8.3.8. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Product
13.6.3. By Type
13.6.4. By End-user
14. Middle East and Africa Point of Care (PoC) Testing Market Analysis
and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn)
14.2. Middle East and Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
14.2.1. Glucose monitoring
14.2.2. Cardiometabolic Monitoring
14.2.3. Albumin Testing
14.2.4. Infectious disease testing
14.2.4.1. HIV Infections
14.2.4.2. Malaria
14.2.4.3. Syphilis
14.2.4.4. E.Coli
14.2.4.5. Influenza
14.2.4.6. Others
14.2.5. Coagulation monitoring
14.2.6. Pregnancy and fertility testing
14.2.7. Cancer marker testing
14.2.8. Urine analysis testing
14.2.9. Cholesterol testing
14.2.10. Hematology testing
14.2.11. Drugs-of-abuse testing
14.2.12. Fecal Occult testing
14.2.13. Covid-19 testing
14.2.14. Others
14.3. Middle East and Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
14.3.1. Prescription Based
14.3.2. Over The Counter (OTC)
14.4. Middle East and Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
14.4.1. Hospitals
14.4.1.1. Critical Care Units
14.4.1.2. Neonatal Intensive Care Unit (NICU)
14.4.1.3. Others
14.4.2. Private Clinics
14.4.3. Diagnostic Centres
14.4.4. Home Care Settings
14.4.5. Ambulatory Care Centers
14.4.6. Emergency Departments
14.4.7. Laboratories
14.4.8. Others
14.5. Middle East and Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.1.1.1. Glucose monitoring
14.5.1.1.2. Cardiometabolic Monitoring
14.5.1.1.3. Albumin Testing
14.5.1.1.4. Infectious disease testing
14.5.1.1.4.1. HIV Infections
14.5.1.1.4.2. Malaria
14.5.1.1.4.3. Syphilis
14.5.1.1.4.4. E.Coli
14.5.1.1.4.5. Influenza
14.5.1.1.4.6. Others
14.5.1.1.5. Coagulation monitoring
14.5.1.1.6. Pregnancy and fertility testing
14.5.1.1.7. Cancer marker testing
14.5.1.1.8. Urine analysis testing
14.5.1.1.9. Cholesterol testing
14.5.1.1.10. Hematology testing
14.5.1.1.11. Drugs-of-abuse testing
14.5.1.1.12. Fecal Occult testing
14.5.1.1.13. Covid-19 testing
14.5.1.1.14. Others
14.5.1.2. Saudi Arabia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.1.2.1. Prescription Based
14.5.1.2.2. Over The Counter (OTC)
14.5.1.3. Saudi Arabia
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.1.3.1. Hospitals
14.5.1.3.1.1. Critical Care Units
14.5.1.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.1.3.1.3. Others
14.5.1.3.2. Private Clinics
14.5.1.3.3. Diagnostic Centres
14.5.1.3.4. Home Care Settings
14.5.1.3.5. Ambulatory Care Centers
14.5.1.3.6. Emergency Departments
14.5.1.3.7. Laboratories
14.5.1.3.8. Others
14.5.2. UAE
14.5.2.1. UAE
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.2.1.1. Glucose monitoring
14.5.2.1.2. Cardiometabolic Monitoring
14.5.2.1.3. Albumin Testing
14.5.2.1.4. Infectious disease testing
14.5.2.1.4.1. HIV Infections
14.5.2.1.4.2. Malaria
14.5.2.1.4.3. Syphilis
14.5.2.1.4.4. E.Coli
14.5.2.1.4.5. Influenza
14.5.2.1.4.6. Others
14.5.2.1.5. Coagulation monitoring
14.5.2.1.6. Pregnancy and fertility testing
14.5.2.1.7. Cancer marker testing
14.5.2.1.8. Urine analysis testing
14.5.2.1.9. Cholesterol testing
14.5.2.1.10. Hematology testing
14.5.2.1.11. Drugs-of-abuse testing
14.5.2.1.12. Fecal Occult testing
14.5.2.1.13. Covid-19 testing
14.5.2.1.14. Others
14.5.2.2. UAE
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.2.2.1. Prescription Based
14.5.2.2.2. Over The Counter (OTC)
14.5.2.3. UAE
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.2.3.1. Hospitals
14.5.2.3.1.1. Critical Care Units
14.5.2.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.2.3.1.3. Others
14.5.2.3.2. Private Clinics
14.5.2.3.3. Diagnostic Centres
14.5.2.3.4. Home Care Settings
14.5.2.3.5. Ambulatory Care Centers
14.5.2.3.6. Emergency Departments
14.5.2.3.7. Laboratories
14.5.2.3.8. Others
14.5.3. Egypt
14.5.3.1. Egypt
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.3.1.1. Glucose monitoring
14.5.3.1.2. Cardiometabolic Monitoring
14.5.3.1.3. Albumin Testing
14.5.3.1.4. Infectious disease testing
14.5.3.1.4.1. HIV Infections
14.5.3.1.4.2. Malaria
14.5.3.1.4.3. Syphilis
14.5.3.1.4.4. E.Coli
14.5.3.1.4.5. Influenza
14.5.3.1.4.6. Others
14.5.3.1.5. Coagulation monitoring
14.5.3.1.6. Pregnancy and fertility testing
14.5.3.1.7. Cancer marker testing
14.5.3.1.8. Urine analysis testing
14.5.3.1.9. Cholesterol testing
14.5.3.1.10. Hematology testing
14.5.3.1.11. Drugs-of-abuse testing
14.5.3.1.12. Fecal Occult testing
14.5.3.1.13. Covid-19 testing
14.5.3.1.14. Others
14.5.3.2. Egypt
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.3.2.1. Prescription Based
14.5.3.2.2. Over The Counter (OTC)
14.5.3.3. Egypt
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.3.3.1. Hospitals
14.5.3.3.1.1. Critical Care Units
14.5.3.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.3.3.1.3. Others
14.5.3.3.2. Private Clinics
14.5.3.3.3. Diagnostic Centres
14.5.3.3.4. Home Care Settings
14.5.3.3.5. Ambulatory Care Centers
14.5.3.3.6. Emergency Departments
14.5.3.3.7. Laboratories
14.5.3.3.8. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.4.1.1. Glucose monitoring
14.5.4.1.2. Cardiometabolic Monitoring
14.5.4.1.3. Albumin Testing
14.5.4.1.4. Infectious disease testing
14.5.4.1.4.1. HIV Infections
14.5.4.1.4.2. Malaria
14.5.4.1.4.3. Syphilis
14.5.4.1.4.4. E.Coli
14.5.4.1.4.5. Influenza
14.5.4.1.4.6. Others
14.5.4.1.5. Coagulation monitoring
14.5.4.1.6. Pregnancy and fertility testing
14.5.4.1.7. Cancer marker testing
14.5.4.1.8. Urine analysis testing
14.5.4.1.9. Cholesterol testing
14.5.4.1.10. Hematology testing
14.5.4.1.11. Drugs-of-abuse testing
14.5.4.1.12. Fecal Occult testing
14.5.4.1.13. Covid-19 testing
14.5.4.1.14. Others
14.5.4.2. Kuwait
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.4.2.1. Prescription Based
14.5.4.2.2. Over The Counter (OTC)
14.5.4.3. Kuwait
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.4.3.1. Hospitals
14.5.4.3.1.1. Critical Care Units
14.5.4.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.4.3.1.3. Others
14.5.4.3.2. Private Clinics
14.5.4.3.3. Diagnostic Centres
14.5.4.3.4. Home Care Settings
14.5.4.3.5. Ambulatory Care Centers
14.5.4.3.6. Emergency Departments
14.5.4.3.7. Laboratories
14.5.4.3.8. Others
14.5.5. South Africa
14.5.5.1. South Africa
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
14.5.5.1.1. Glucose monitoring
14.5.5.1.2. Cardiometabolic Monitoring
14.5.5.1.3. Albumin Testing
14.5.5.1.4. Infectious disease testing
14.5.5.1.4.1. HIV Infections
14.5.5.1.4.2. Malaria
14.5.5.1.4.3. Syphilis
14.5.5.1.4.4. E.Coli
14.5.5.1.4.5. Influenza
14.5.5.1.4.6. Others
14.5.5.1.5. Coagulation monitoring
14.5.5.1.6. Pregnancy and fertility testing
14.5.5.1.7. Cancer marker testing
14.5.5.1.8. Urine analysis testing
14.5.5.1.9. Cholesterol testing
14.5.5.1.10. Hematology testing
14.5.5.1.11. Drugs-of-abuse testing
14.5.5.1.12. Fecal Occult testing
14.5.5.1.13. Covid-19 testing
14.5.5.1.14. Others
14.5.5.2. South Africa
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.5.2.1. Prescription Based
14.5.5.2.2. Over The Counter (OTC)
14.5.5.3. South Africa
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
14.5.5.3.1. Hospitals
14.5.5.3.1.1. Critical Care Units
14.5.5.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.5.3.1.3. Others
14.5.5.3.2. Private Clinics
14.5.5.3.3. Diagnostic Centres
14.5.5.3.4. Home Care Settings
14.5.5.3.5. Ambulatory Care Centers
14.5.5.3.6. Emergency Departments
14.5.5.3.7. Laboratories
14.5.5.3.8. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
14.5.6.1.1. Glucose monitoring
14.5.6.1.2. Cardiometabolic Monitoring
14.5.6.1.3. Albumin Testing
14.5.6.1.4. Infectious disease testing
14.5.6.1.4.1. HIV Infections
14.5.6.1.4.2. Malaria
14.5.6.1.4.3. Syphilis
14.5.6.1.4.4. E.Coli
14.5.6.1.4.5. Influenza
14.5.6.1.4.6. Others
14.5.6.1.5. Coagulation monitoring
14.5.6.1.6. Pregnancy and fertility testing
14.5.6.1.7. Cancer marker testing
14.5.6.1.8. Urine analysis testing
14.5.6.1.9. Cholesterol testing
14.5.6.1.10. Hematology testing
14.5.6.1.11. Drugs-of-abuse testing
14.5.6.1.12. Fecal Occult testing
14.5.6.1.13. Covid-19 testing
14.5.6.1.14. Others
14.5.6.2. Rest of Middle East & Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.6.2.1. Prescription Based
14.5.6.2.2. Over The Counter (OTC)
14.5.6.3. Rest of Middle East & Africa Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
14.5.6.3.1. Hospitals
14.5.6.3.1.1. Critical Care Units
14.5.6.3.1.2. Neonatal Intensive Care Unit (NICU)
14.5.6.3.1.3. Others
14.5.6.3.2. Private Clinics
14.5.6.3.3. Diagnostic Centres
14.5.6.3.4. Home Care Settings
14.5.6.3.5. Ambulatory Care Centers
14.5.6.3.6. Emergency Departments
14.5.6.3.7. Laboratories
14.5.6.3.8. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Product
14.6.3. By Type
14.6.4. By End-user
15. Latin America Point of Care (PoC) Testing Market Analysis
and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America
Point of Care (PoC) Testing Market Revenue (US$ Mn)
15.2. Latin America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
15.2.1. Glucose monitoring
15.2.2. Cardiometabolic Monitoring
15.2.3. Albumin Testing
15.2.4. Infectious disease testing
15.2.4.1. HIV Infections
15.2.4.2. Malaria
15.2.4.3. Syphilis
15.2.4.4. E.Coli
15.2.4.5. Influenza
15.2.4.6. Others
15.2.5. Coagulation monitoring
15.2.6. Pregnancy and fertility testing
15.2.7. Cancer marker testing
15.2.8. Urine analysis testing
15.2.9. Cholesterol testing
15.2.10. Hematology testing
15.2.11. Drugs-of-abuse testing
15.2.12. Fecal Occult testing
15.2.13. Covid-19 testing
15.2.14. Others
15.3. Latin America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
15.3.1. Prescription Based
15.3.2. Over The Counter (OTC)
15.4. Latin America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
15.4.1. Hospitals
15.4.1.1. Critical Care Units
15.4.1.2. Neonatal Intensive Care Unit (NICU)
15.4.1.3. Others
15.4.2. Private Clinics
15.4.3. Diagnostic Centres
15.4.4. Home Care Settings
15.4.5. Ambulatory Care Centers
15.4.6. Emergency Departments
15.4.7. Laboratories
15.4.8. Others
15.5. Latin America
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
15.5.1.1.1. Glucose monitoring
15.5.1.1.2. Cardiometabolic Monitoring
15.5.1.1.3. Albumin Testing
15.5.1.1.4. Infectious disease testing
15.5.1.1.4.1. HIV Infections
15.5.1.1.4.2. Malaria
15.5.1.1.4.3. Syphilis
15.5.1.1.4.4. E.Coli
15.5.1.1.4.5. Influenza
15.5.1.1.4.6. Others
15.5.1.1.5. Coagulation monitoring
15.5.1.1.6. Pregnancy and fertility testing
15.5.1.1.7. Cancer marker testing
15.5.1.1.8. Urine analysis testing
15.5.1.1.9. Cholesterol testing
15.5.1.1.10. Hematology testing
15.5.1.1.11. Drugs-of-abuse testing
15.5.1.1.12. Fecal Occult testing
15.5.1.1.13. Covid-19 testing
15.5.1.1.14. Others
15.5.1.2. Brazil
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.1.2.1. Prescription Based
15.5.1.2.2. Over The Counter (OTC)
15.5.1.3. Brazil
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
15.5.1.3.1. Hospitals
15.5.1.3.1.1. Critical Care Units
15.5.1.3.1.2. Neonatal Intensive Care Unit (NICU)
15.5.1.3.1.3. Others
15.5.1.3.2. Private Clinics
15.5.1.3.3. Diagnostic Centres
15.5.1.3.4. Home Care Settings
15.5.1.3.5. Ambulatory Care Centers
15.5.1.3.6. Emergency Departments
15.5.1.3.7. Laboratories
15.5.1.3.8. Others
15.5.2. Argentina
15.5.2.1. Argentina
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Product
15.5.2.1.1. Glucose monitoring
15.5.2.1.2. Cardiometabolic Monitoring
15.5.2.1.3. Albumin Testing
15.5.2.1.4. Infectious disease testing
15.5.2.1.4.1. HIV Infections
15.5.2.1.4.2. Malaria
15.5.2.1.4.3. Syphilis
15.5.2.1.4.4. E.Coli
15.5.2.1.4.5. Influenza
15.5.2.1.4.6. Others
15.5.2.1.5. Coagulation monitoring
15.5.2.1.6. Pregnancy and fertility testing
15.5.2.1.7. Cancer marker testing
15.5.2.1.8. Urine analysis testing
15.5.2.1.9. Cholesterol testing
15.5.2.1.10. Hematology testing
15.5.2.1.11. Drugs-of-abuse testing
15.5.2.1.12. Fecal Occult testing
15.5.2.1.13. Covid-19 testing
15.5.2.1.14. Others
15.5.2.2. Argentina
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.2.2.1. Prescription Based
15.5.2.2.2. Over The Counter (OTC)
15.5.2.3. Argentina
Point of Care (PoC) Testing Market Revenue (US$ Mn) and Forecasts, By
End-user
15.5.2.3.1. Hospitals
15.5.2.3.1.1. Critical Care Units
15.5.2.3.1.2. Neonatal Intensive Care Unit (NICU)
15.5.2.3.1.3. Others
15.5.2.3.2. Private Clinics
15.5.2.3.3. Diagnostic Centres
15.5.2.3.4. Home Care Settings
15.5.2.3.5. Ambulatory Care Centers
15.5.2.3.6. Emergency Departments
15.5.2.3.7. Laboratories
15.5.2.3.8. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Product
15.5.3.1.1. Glucose monitoring
15.5.3.1.2. Cardiometabolic Monitoring
15.5.3.1.3. Albumin Testing
15.5.3.1.4. Infectious disease testing
15.5.3.1.4.1. HIV Infections
15.5.3.1.4.2. Malaria
15.5.3.1.4.3. Syphilis
15.5.3.1.4.4. E.Coli
15.5.3.1.4.5. Influenza
15.5.3.1.4.6. Others
15.5.3.1.5. Coagulation monitoring
15.5.3.1.6. Pregnancy and fertility testing
15.5.3.1.7. Cancer marker testing
15.5.3.1.8. Urine analysis testing
15.5.3.1.9. Cholesterol testing
15.5.3.1.10. Hematology testing
15.5.3.1.11. Drugs-of-abuse testing
15.5.3.1.12. Fecal Occult testing
15.5.3.1.13. Covid-19 testing
15.5.3.1.14. Others
15.5.3.2. Rest of Latin America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.3.2.1. Prescription Based
15.5.3.2.2. Over The Counter (OTC)
15.5.3.3. Rest of Latin America Point of Care (PoC) Testing Market Revenue
(US$ Mn) and Forecasts, By End-user
15.5.3.3.1. Hospitals
15.5.3.3.1.1. Critical Care Units
15.5.3.3.1.2. Neonatal Intensive Care Unit (NICU)
15.5.3.3.1.3. Others
15.5.3.3.2. Private Clinics
15.5.3.3.3. Diagnostic Centres
15.5.3.3.4. Home Care Settings
15.5.3.3.5. Ambulatory Care Centers
15.5.3.3.6. Emergency Departments
15.5.3.3.7. Laboratories
15.5.3.3.8. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Product
15.6.3. By Type
15.6.4. By End-user
16. Competitive Benchmarking
16.1. Market Share Analysis, 2021
16.2. Global Presence and Growth Strategies
16.2.1. Mergers and Acquisitions
16.2.2. Product Launches
16.2.3. Investments Trends
16.2.4. R&D Initiatives
17. Player Profiles
17.1. Abbott
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. AccuBioTech Co., Ltd.
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. BD
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Beckman Coulter, Inc.
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Chembio Diagnostics, Inc.
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Danaher
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. EKF Diagnostics
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. F. Hoffmann-La Roche Ltd
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. PTS Diagnostics
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Sekisui Diagnostics
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Siemens Healthcare Private Limited
17.11.1. Company Details
17.11.2. Company Overview
17.11.3. Product Offerings
17.11.4. Key Developments
17.11.5. Financial Analysis
17.11.6. SWOT Analysis
17.11.7. Business Strategies
17.12. Thermo Fisher Scientific
17.12.1. Company Details
17.12.2. Company Overview
17.12.3. Product Offerings
17.12.4. Key Developments
17.12.5. Financial Analysis
17.12.6. SWOT Analysis
17.12.7. Business Strategies
17.13. Trinity Biotech
17.13.1. Company Details
17.13.2. Company Overview
17.13.3. Product Offerings
17.13.4. Key Developments
17.13.5. Financial Analysis
17.13.6. SWOT Analysis
17.13.7. Business Strategies
17.14. Other market participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.